NES/Bio-XL

Website
AI,BioTech,HealthTech

Company Bio

Founders

LvlUp insightsGenerated from LvlUp’s portfolio data and the company’s own updates
Similar companies

More in the LvlUp portfolio

See all →

Building something ambitious?

LvlUp Ventures backs founders from first check to late stage.

Apply for funding
Meir Azulay, Mazal Dahan
Pre-Seed
Israel
AI, BioTech, HealthTech
2017
NES is incubated within Bio-XL and will spun off as an independent company following fundraising, with all IP owned by NES. The company will lead preclinical development through IND submission and early clinical trials, while partnering or out-licensing regional or global rights for late-stage development, regulatory approval, commercialization, and distribution. Following clinical validation, the platform will expand to additional neurodegenerative indications while maintaining R&D and manufacturing capabilities.

NES (NeuroSave) is developing a first-in-class therapy to prevent dementia by targeting glutamate-driven neurotoxicity at the Mild Cognitive Impairment (MCI) stage. Early intervention aims to prevent disease progression before irreversible brain damage occurs.